Welcome to IPCOR
What is the Irish Prostate Cancer Outcomes Research?
IPCOR created the first national prostate cancer registry in Ireland. This registry contains clinical and quality of life data on 6816 men who were diagnosed with prostate cancer and treated in 16 hospitals around Ireland between 2016 and 2020.
The IPCOR registry has now returned in 2024 as a clinical quality and outcomes registry to collect longitudinal clinical data on men undergoing diagnosis and treatment for prostate cancer. Along with clinical data and quality of life measures including patient reported outcomes measurements (PROMs), IPCOR has also established a biorepository for blood and urine samples of men who consent to participate, as well as access to their routine prostate tissue. In the first phase of this second edition, IPCOR will be operational at 5 major hospital sites in Dublin and Galway.
The IPCOR dataset is being used to answer several policy and research questions regarding how men are diagnosed with prostate cancer, how they are treated, how those treatments affect them and how they do in the longer term. The second phase of IPCOR has allowed the creation of an infrastructure for both clinical and translational research processes. More information on collaborations and access to data can be seen in Data Access Policies. We aim to use this data to work with doctors, hospitals and policy-makers around Ireland to improve prostate cancer care for men in Ireland.
Who carried out the IPCOR programme?
IPCOR is a solely Movember funded project, managed and owned by the School of Medicine, University College Dublin (UCD). The Principal Investigator of IPCOR is Associate Clinical Professor David Galvin.
2016 to 2020
A research partnership of Clinical Research Development Ireland, the National Cancer Registry Ireland and Health Research Board Clinical Research Facility Galway worked together to set up the registry with funding of €1.75 million from Movember, in partnership with the Irish Cancer Society. When the registry stopped collecting data, the de-identified data was transferred from Clinical Research Development Ireland to University College Dublin where it is currently being analysed by the IPCOR team.
If you were diagnosed with prostate cancer between 2016 and 2019, your de-identified information may be included in the IPCOR dataset. If you would like to request removal from the dataset, please click here.
Follow us on Twitter: @IPCOR_Ireland
Follow us on LinkedIn: @IPCOR Ireland
IPCOR is developing a Registry of men who have been newly diagnosed with Prostate Cancer in Ireland
Read More